AI Drug Discovery
AI-designed Drug Rentosertib Advances Into Phase III Trial for Idiopathic Pulmonary Fibrosis
2026-07-08
Insilico Medicine and SK Biopharmaceuticals Announce Up to $2.5 Billion AI Neuroimmune Drug Collaboration
2026-06-22
Insilico Medicine’s ISM8969 Enters Phase 1 Trial, Advancing Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation and CNS Disorders
2026-06-18
Eli Lilly and Insilico Medicine Seal $2.75B AI Drug Discovery Partnership After FTC Clearance
2026-03-30
Insilico Medicine Launches PandaClaw AI Agent and Expands Partnership with ASKA to Transform Women’s Health Drug Discovery
2026-03-24
Liquid AI and Insilico Launch LFM2-2.6B-MMAI: Lightweight Model for On-Premise Drug Discovery
2026-03-04
Reprogramming Protein Homeostasis: Lyterian’s Patient-Focused Mission to Rethink Oncology and Neurodegeneration
2026-03-03
LATEST
EVENT
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan





